CEO Andy McNeill and client, Christine Damico of Johnson & Johnson, talk about the changing face of pharmaceutical meetings. With many off-patent drugs coming up, cut-backs are discussed such as the size, length and frequency of face-to-face meetings. This article offers insight from the perspective of both the pharmaceutical company and meeting planners alike. Despite the recession, it is agreed that corporate meetings are a very effective way to gather information, train staff, and get doctors comfortable with new and potential drugs.
